Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment Lana X. Tong, BA, Julie Jackson, MD, Justin Kerstetter, MD, Scott D. Worswick, MD Journal of the American Academy of Dermatology Volume 70, Issue 3, Pages e59-e60 (March 2014) DOI: 10.1016/j.jaad.2013.09.035 Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Disseminated HSV infection in a patient treated with ruxolitinib. Subcutaneous edema of the face, bifrontal scalp ulcerations, and hemorrhagic crusting of the conjunctival, nasal, and oral mucosae. Journal of the American Academy of Dermatology 2014 70, e59-e60DOI: (10.1016/j.jaad.2013.09.035) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 Disseminated HSV infection in a patient treated with ruxolitinib. Necrotizing inflammation with numerous foci of necrosis in the dermis, confluent epidermal necrosis, and fibrinopurulent exudate. Arrow indicates viral inclusion within a keratinocyte. Hematoxylin-eosin stain; ×40. Journal of the American Academy of Dermatology 2014 70, e59-e60DOI: (10.1016/j.jaad.2013.09.035) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions